Advances in the discovery and development of melanoma drug therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in the discovery and development of melanoma drug therapies
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume -, Issue -, Pages 1-29
Publisher
Informa UK Limited
Online
2021-06-23
DOI
10.1080/17460441.2021.1942834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma
- (2021) Cara Haymaker et al. Cancer Discovery
- Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
- (2021) Stergios J. Moschos et al. MELANOMA RESEARCH
- Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review
- (2021) Kerianne Boulva et al. Cancers
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
- (2020) Meenu Sharma et al. Nature Communications
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- (2020) Alexander M. M. Eggermont et al. JAMA Oncology
- Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
- (2020) Natalia Maximova et al. Journal for ImmunoTherapy of Cancer
- The discovery and development of binimetinib for the treatment of melanoma
- (2020) Brian Tran et al. Expert Opinion on Drug Discovery
- Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
- (2020) Vera Petrova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cutaneous melanoma and the immunotherapy revolution (Review)
- (2020) Giulia Leonardi et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
- (2020) Li Li et al. Scientific Reports
- Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
- (2019) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Daniel G. Coit et al. Journal of the National Comprehensive Cancer Network
- BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
- (2019) Erinna F. Lee et al. Cell Death & Disease
- Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
- (2019) Henry T. Quach et al. JAMA Oncology
- Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
- (2019) Yenny Angela et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current state of melanoma diagnosis and treatment
- (2019) Lauren E. Davis et al. CANCER BIOLOGY & THERAPY
- 1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
- (2019) J S Weber et al. ANNALS OF ONCOLOGY
- Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
- (2019) P G Corrie et al. ANNALS OF ONCOLOGY
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Improved durable responses regardless of age following cytoreduction and “no-tourniquet” hyperthermic isolated limb chemotherapy for in transit melanoma of the extremity
- (2019) Ton Wang et al. AMERICAN JOURNAL OF SURGERY
- Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
- (2019) Hugo Herrscher et al. CURRENT OPINION IN ONCOLOGY
- Regional therapies for locoregionally advanced and unresectable melanoma
- (2018) Evan S. Weitman et al. CLINICAL & EXPERIMENTAL METASTASIS
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
- (2018) Jaquelyn N. Sanchez et al. DRUGS
- Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine
- (2018) Mark O Hardin et al. Immunotherapy
- Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study
- (2018) Tavis A. Read et al. JOURNAL OF SURGICAL ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Talimogene laherparepvec: First in class oncolytic virotherapy
- (2018) Robert M. Conry et al. Human Vaccines & Immunotherapeutics
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Encorafenib and Binimetinib: First Global Approvals
- (2018) Matt Shirley DRUGS
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
- (2018) Luke D. Rothermel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
- (2018) Yang Liu et al. TRENDS IN IMMUNOLOGY
- Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
- (2018) Maartje W. Rohaan et al. Journal for ImmunoTherapy of Cancer
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
- (2017) Petros Fessas et al. SEMINARS IN ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors
- (2016) Frederique M. Poulet et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Talimogene Laherparepvec for the Treatment of Advanced Melanoma
- (2016) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside
- (2016) Eva Hornig et al. EXPERIMENTAL DERMATOLOGY
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation
- (2016) Anissa S. H. Chan et al. PLoS One
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
- (2015) Zeynep Eroglu et al. Therapeutic Advances in Medical Oncology
- The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options
- (2015) Emmanuel Gabriel et al. Cancers
- Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy
- (2014) Francesca Pretto et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy in the management of advanced cutaneous malignant melanoma
- (2013) Jason J. Luke et al. CLINICS IN DERMATOLOGY
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
- (2013) Brijal M. Desai et al. PLoS One
- U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma
- (2012) T. M. Herndon et al. ONCOLOGIST
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis
- (2009) Kristin Turza et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Understanding Signaling Cascades in Melanoma
- (2008) Pablo Lopez-Bergami et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search